| __timestamp | Perrigo Company plc | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2613100000 | 3243000 |
| Thursday, January 1, 2015 | 2891500000 | 2472000 |
| Friday, January 1, 2016 | 3228800000 | 2548000 |
| Sunday, January 1, 2017 | 2966700000 | 19623000 |
| Monday, January 1, 2018 | 2900200000 | 30421000 |
| Tuesday, January 1, 2019 | 3064100000 | 32793999 |
| Wednesday, January 1, 2020 | 3248100000 | 28304000 |
| Friday, January 1, 2021 | 2722500000 | 620000 |
| Saturday, January 1, 2022 | 2996200000 | 755000 |
| Sunday, January 1, 2023 | 2975200000 | 1322000 |
Igniting the spark of knowledge
In the ever-evolving landscape of pharmaceuticals, understanding cost efficiency is crucial. Perrigo Company plc and Viridian Therapeutics, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Perrigo's cost of revenue has shown remarkable stability, averaging around $3 billion annually. This consistency underscores Perrigo's robust operational efficiency. In contrast, Viridian's cost of revenue has fluctuated significantly, peaking at $32.8 million in 2019 before dropping to just $755,000 in 2022. This volatility reflects Viridian's dynamic growth phase and strategic pivots.
Perrigo's cost efficiency highlights its established market presence, while Viridian's fluctuations suggest a company in transition, potentially poised for future growth. Investors and industry watchers should note these trends as they reflect broader strategic directions and market positioning.
Cost of Revenue: Key Insights for GSK plc and Viridian Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Incyte Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Grifols, S.A. and Perrigo Company plc
Cost Insights: Breaking Down PTC Therapeutics, Inc. and Perrigo Company plc's Expenses
Analyzing Cost of Revenue: Perrigo Company plc and Supernus Pharmaceuticals, Inc.
Cost of Revenue Trends: Perrigo Company plc vs Celldex Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: HUTCHMED (China) Limited vs Viridian Therapeutics, Inc.
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.
Geron Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Iovance Biotherapeutics, Inc. vs Viridian Therapeutics, Inc.
Cost of Revenue: Key Insights for Wave Life Sciences Ltd. and Viridian Therapeutics, Inc.